Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

1. Cassava Sciences, Inc. faces a class action lawsuit over alleged securities fraud. 2. The lawsuit targets investors affected between February 7, 2024, and November 24, 2024. 3. Simufilam's Phase 3 study 'ReThink-ALZ' failed to meet endpoints and underperformed. 4. Cassava's stock plummeted 83.76% from $26.48 to $4.30 in one day. 5. Investors may seek recovery for losses without upfront fees.

Legal

85

4m saved

Insight

Article

FAQ

Why Very Bearish?

The substantial stock price decline following negative trial results indicates severe investor loss, likely further impacting SAVA's market perception.

How important is it?

The class action lawsuit reflects potential liability for investors, likely to sway future stock valuations against SAVA.

Why Short Term?

Immediate market fears due to the lawsuit and trial failures will affect SAVA's price quickly, but recovery could be possible if future developments improve outcomes.

Related Companies

SAVA NASDAQ

NEW YORK, Feb. 7, 2025 /PRNewswire/ --

Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127514&wire=4

SAVA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included, among other things, clear confidence in simufilam's ability to treat Alzheimer's Disease. On November 25, 2024, Cassava released topline results for the first of its two ongoing Phase 3 studies on simufilam, the "ReThink-ALZ" study. The results indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo. Following this news, the price of Cassava's common stock declined dramatically. From a closing market price of $26.48 per share on November 22, 2024, Cassava's stock price fell to $4.30 per share on November 25, 2024, a decline of about 83.76% in the span of just a single day.

WHAT'S NEXT?

If you suffered a loss in Cassava Sciences, Inc. during the relevant time frame, you have until February 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP